Search

Your search keyword '"Petit, Thierry"' showing total 938 results

Search Constraints

Start Over You searched for: Author "Petit, Thierry" Remove constraint Author: "Petit, Thierry"
938 results on '"Petit, Thierry"'

Search Results

3. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial

4. A Constraint Programming Approach to Weighted Isomorphic Mapping of Fragment-based Shape Signatures

5. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database

6. Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials

8. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort

9. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort

10. Contributors

13. Weekly paclitaxel (P), carboplatin (CP) plus pembrolizumab (PMB) as first-line treatment of recurrent or metastatic (R/M) or locally very advanced (LVA) head and neck squamous cell carcinoma (HNSCC): A retrospective study in 39 patients (pts).

14. Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France

15. Anti-reflux surgery in children with congenital diaphragmatic hernia: A prospective cohort study on a controversial practice

16. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

17. Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer

19. 'Model and Run' Constraint Networks with a MILP Engine

20. Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort

21. Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic

22. Risk Factors of Early Mortality and Morbidity in Esophageal Atresia with Distal Tracheoesophageal Fistula: A Population-Based Cohort Study

23. Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program

24. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023

25. Impact of body mass index on overall survival in patients with metastatic breast cancer

26. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database

27. Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

28. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort

29. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

30. COVID-19 et personnes suivies pour un cancer du sein : recommandations françaises pour la pratique clinique de Nice-St Paul de Vence, en collaboration avec le Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), la Société d’Imagerie de la Femme (SIFEM), la Société Française de Chirurgie Oncologique (SFCO), la Société Française de Sénologie et Pathologie Mammaire (SFSPM) et le French Breast Cancer Intergroup-UNICANCER (UCBG)

31. Low RNA disruption during neoadjuvant chemotherapy predicts pCR absence in patients with breast cancer

32. Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer

33. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort

34. Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

35. Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

36. Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

37. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023

38. Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

40. Dynamic Sweep Filtering Algorithm for FlexC

41. The Energetic Reasoning Checker Revisited

44. Three Generalizations of the FOCUS Constraint

45. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort

47. Predictors of the Performance of Early Antireflux Surgery in Esophageal Atresia

48. A Generalized Arc-Consistency Algorithm for a Class of Counting Constraints: Revised Edition that Incorporates One Correction

49. Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort

50. The Soft Cumulative Constraint

Catalog

Books, media, physical & digital resources